Aura Biosciences (NASDAQ:AURA) Reaches New 52-Week High on Analyst Upgrade

Aura Biosciences, Inc. (NASDAQ:AURA)’s share price hit a new 52-week high during mid-day trading on Friday after HC Wainwright raised their price target on the stock from $21.00 to $22.00. HC Wainwright currently has a buy rating on the stock. Aura Biosciences traded as high as $12.38 and last traded at $11.82, with a volume of 585739 shares traded. The stock had previously closed at $10.29.

Several other research firms have also issued reports on AURA. JMP Securities lifted their price target on shares of Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a report on Friday, September 13th. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 9th. Finally, Evercore ISI raised Aura Biosciences to a “strong-buy” rating in a report on Monday, September 16th. Three analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Aura Biosciences currently has a consensus rating of “Buy” and an average target price of $22.00.

Insider Transactions at Aura Biosciences

In related news, CTO Mark Plavsic sold 7,383 shares of the firm’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total value of $72,722.55. Following the completion of the transaction, the chief technology officer now owns 121,132 shares in the company, valued at $1,193,150.20. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Aura Biosciences

Institutional investors and hedge funds have recently modified their holdings of the business. Regency Capital Management Inc. DE increased its position in shares of Aura Biosciences by 11.4% in the first quarter. Regency Capital Management Inc. DE now owns 785,136 shares of the company’s stock valued at $6,163,000 after buying an additional 80,162 shares in the last quarter. American International Group Inc. lifted its position in shares of Aura Biosciences by 27.4% in the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after acquiring an additional 3,782 shares in the last quarter. Levin Capital Strategies L.P. grew its holdings in shares of Aura Biosciences by 11.2% during the first quarter. Levin Capital Strategies L.P. now owns 111,200 shares of the company’s stock worth $873,000 after buying an additional 11,200 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Aura Biosciences in the first quarter valued at about $144,000. Finally, Bank of New York Mellon Corp lifted its stake in shares of Aura Biosciences by 51.4% in the second quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock worth $1,081,000 after buying an additional 48,549 shares in the last quarter. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Aura Biosciences Trading Up 13.5 %

The stock’s fifty day simple moving average is $8.59 and its 200 day simple moving average is $8.03. The company has a market cap of $578.66 million, a price-to-earnings ratio of -5.53 and a beta of 0.37.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.04. On average, analysts predict that Aura Biosciences, Inc. will post -1.7 EPS for the current year.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.